Elyse Couch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Elyse Couch has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
Emmanuelle Belanger
Department of Health Services, Policy, and Practice Brown University School of Public Health Providence Rhode Island USA
6 shared publicationsMatthew Prina
Population Health Sciences Institute, Newcastle University , Newcastle upon Tyne
6 shared publicationsVanessa Lawrence
Institute of Psychiatry, Psychology, and Neuroscience, King’s College London, London, UK
3 shared publicationsWenhan Zhang
Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA
3 shared publicationsChristoph Mueller
Institute of Psychiatry, Psychology, and Neuroscience, King’s College London, London, UK
2 shared publicationsCourtney H. Van Houtven
Department of Population Health Science Duke University School of Medicine Durham North Carolina USA
2 shared publications
Latest Publications
- Open Access
- 12 July 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (7) , e71665
Adoption of Alzheimer's disease biomarkers by primary care clinicians: findings from the National Dementia Workforce Study
INTRODUCTION: Biomarkers for Alzheimer's disease (AD) are now available for clinical use; however, little is known about their use in primary care. METHODS: Cross‐sectional analysis of 2024 data from the National Dementia Workforce Study, a nationally representative survey of primary care providers (PCPs) who treat Medicare beneficiaries with dementia. We used survey weights to generate nationally representative estimates of self‐reported biomarker use. RESULTS: Among 2574 PCPs, computed tomography/magnetic resonance imaging (CT/MRI) (79%) and neuropsychological testing (71%) were most commonly used, followed by positron emission tomography (PET) (18%), plasma (16%), genetic (14%), and CSF testing (9%). PCPs confident in diagnosing dementia and from specialist settings were more likely to report ordering PET, plasma, genetic, and CSF testing. DISCUSSION: This study describes patterns in the adoption of AD biomarkers in the year after Medicare expanded coverage for some biomarkers, providing a baseline for measuring changes in biomarker use. Guidelines are needed to inform PCP decision‐making for biomarkers.
- 12 July 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (7) , e71665
Open AccessAdoption of Alzheimer's disease biomarkers by primary care clinicians: findings from the National Dementia Workforce Study
INTRODUCTION: Biomarkers for Alzheimer's disease (AD) are now available for clinical use; however, little is known about their use in primary care. METHODS: Cross‐sectional analysis of 2024 data from the National Dementia Workforce Study, a nationally representative survey of primary care providers (PCPs) who treat Medicare beneficiaries with dementia. We used survey weights to generate nationally representative estimates of self‐reported biomarker use. RESULTS: Among 2574 PCPs, computed tomography/magnetic resonance imaging (CT/MRI) (79%) and neuropsychological testing (71%) were most commonly used, followed by positron emission tomography (PET) (18%), plasma (16%), genetic (14%), and CSF testing (9%). PCPs confident in diagnosing dementia and from specialist settings were more likely to report ordering PET, plasma, genetic, and CSF testing. DISCUSSION: This study describes patterns in the adoption of AD biomarkers in the year after Medicare expanded coverage for some biomarkers, providing a baseline for measuring changes in biomarker use. Guidelines are needed to inform PCP decision‐making for biomarkers.
- 16 June 2026
- Published by Wiley in International Journal of Geriatric Psychiatry
- Vol. 41 (6) , e70226
Long‐Term Perceptions of the Value of Amyloid PET Scans Among Cognitively Impaired Medicare Beneficiaries and Their Care Partners
Objectives: The objective of this study was to examine the long‐term perceptions of the value of receiving an amyloid PET scan, a test used to diagnose Alzheimer's disease, among Medicare beneficiaries with cognitive impairment and their care partners. Methods: An exploratory qualitative research design was used. A total of 100 in‐depth semi‐structured interviews were conducted with a purposeful sample of CARE‐IDEAS participants two to three years post‐scan. A team of coders applied qualitative content analysis to identify content about the value of the scan, which was then analyzed using thematic analysis, and stratified by diagnostic category (mild cognitive impairment vs. dementia) and scan results (elevated amyloid vs. not elevated). Results: A majority of amyloid PET scan recipients and their care partners emphasized major benefits of receiving the scan including increased certainty about diagnosis, the ability to prepare for the future, potentially accessing treatment or trials, the ability to contribute to research, and limited procedural risks. Some participants also reported concerns about the cost of the scan, the lack of effective treatment options and clear prognostic information, the limited impact on their lives or treatment plans, and the emotional toll of living with the results. Their views and endorsements of the scan were shaped by their health and personal circumstances (e.g., seen as less relevant among those with rapidly declining health), and by their preference for more information and involvement in decision‐making. Conclusion: The perspectives of persons living with cognitive impairment and their care partners about the value of amyloid PET scans differed across disease trajectories and personal circumstances. These experiences should be taken into consideration when advising symptomatic patients on the benefits and drawbacks of biomarkers for Alzheimer's disease.
- 16 June 2026
- Published by Wiley in International Journal of Geriatric Psychiatry
- Vol. 41 (6) , e70226
Long‐Term Perceptions of the Value of Amyloid PET Scans Among Cognitively Impaired Medicare Beneficiaries and Their Care Partners
Objectives: The objective of this study was to examine the long‐term perceptions of the value of receiving an amyloid PET scan, a test used to diagnose Alzheimer's disease, among Medicare beneficiaries with cognitive impairment and their care partners. Methods: An exploratory qualitative research design was used. A total of 100 in‐depth semi‐structured interviews were conducted with a purposeful sample of CARE‐IDEAS participants two to three years post‐scan. A team of coders applied qualitative content analysis to identify content about the value of the scan, which was then analyzed using thematic analysis, and stratified by diagnostic category (mild cognitive impairment vs. dementia) and scan results (elevated amyloid vs. not elevated). Results: A majority of amyloid PET scan recipients and their care partners emphasized major benefits of receiving the scan including increased certainty about diagnosis, the ability to prepare for the future, potentially accessing treatment or trials, the ability to contribute to research, and limited procedural risks. Some participants also reported concerns about the cost of the scan, the lack of effective treatment options and clear prognostic information, the limited impact on their lives or treatment plans, and the emotional toll of living with the results. Their views and endorsements of the scan were shaped by their health and personal circumstances (e.g., seen as less relevant among those with rapidly declining health), and by their preference for more information and involvement in decision‐making. Conclusion: The perspectives of persons living with cognitive impairment and their care partners about the value of amyloid PET scans differed across disease trajectories and personal circumstances. These experiences should be taken into consideration when advising symptomatic patients on the benefits and drawbacks of biomarkers for Alzheimer's disease.
- Open Access
- 9 February 2026
- Published by SAGE Publications in Journal of Applied Gerontology
A Mixed-Methods Study of End-of-Life Care in Assisted Living During the COVID-19 Pandemic: National Survey of Administrators and In-Depth Interviews With Bereaved Next of Kin
Using a national survey of assisted living administrators ( n = 2,084) and interviews with residents’ bereaved next of kin ( n = 30), we describe policies administrators reported complying with at the worst of the COVID-19 pandemic and explore relationships between COVID-19-related policies and bereaved next-of-kin’s perceptions of end-of-life care quality, integrating findings to develop a comprehensive examination of end-of-life care in assisted living. During the pandemic, most administrators reported allowing compassionate care visits and hospice services. Next of kin described limited visitation and external care services and declines in residents’ physical, mental, and social well-being, emphasizing the difficulty of missing precious time together. This study examines next-of-kin experiences of residents who died during the COVID-19 pandemic, providing evidence to inform future infection control policies.
- 9 February 2026
- Published by SAGE Publications in Journal of Applied Gerontology
Open AccessA Mixed-Methods Study of End-of-Life Care in Assisted Living During the COVID-19 Pandemic: National Survey of Administrators and In-Depth Interviews With Bereaved Next of Kin
Using a national survey of assisted living administrators ( n = 2,084) and interviews with residents’ bereaved next of kin ( n = 30), we describe policies administrators reported complying with at the worst of the COVID-19 pandemic and explore relationships between COVID-19-related policies and bereaved next-of-kin’s perceptions of end-of-life care quality, integrating findings to develop a comprehensive examination of end-of-life care in assisted living. During the pandemic, most administrators reported allowing compassionate care visits and hospice services. Next of kin described limited visitation and external care services and declines in residents’ physical, mental, and social well-being, emphasizing the difficulty of missing precious time together. This study examines next-of-kin experiences of residents who died during the COVID-19 pandemic, providing evidence to inform future infection control policies.
- Open Access
- 29 December 2025
- Published by Wiley in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
- Vol. 18 (1)
Prevalence and predictors of diagnosed mild cognitive impairment among Medicare beneficiaries
INTRODUCTION: Mild cognitive impairment (MCI) is a known risk factor for dementia and presents an opportunity for early engagement in preventative strategies, treatment, and advanced planning. However, little is known about MCI diagnosis rates among Medicare beneficiaries. METHODS: Using data from the 2014 to 2022 rounds of the National Health and Aging Trends Study (NHATS) linked with Medicare claims data, we identified the proportion of beneficiaries with symptoms of MCI, as defined by an NHATS algorithm, who received a diagnosis according to International Classification of Diseases codes. Univariate and multivariate logistic regressions were used to identify predictors of diagnosed MCI. RESULTS: Of beneficiaries identified by the NHATS algorithm, 10.6% had a recorded diagnosis of MCI. Odds of diagnosis were higher among women and beneficiaries with a bachelor's degree or higher, and lower among beneficiaries who attended doctor visits alone. DISCUSSION: Targeted initiatives are needed to increase MCI diagnosis rates, particularly in the era of novel diagnostic tests and therapies. Highlights: We linked National Health and Aging Trends Study data to Medicare claims to identify the prevalence of diagnosed mild cognitive impairment (MCI). We identified 10.6% of Medicare beneficiaries with symptoms of MCI who have a diagnosis. Women and people with a bachelor's degree were more likely to have an MCI diagnosis. People who visited the doctor alone were less likely to have an MCI diagnosis.
- 29 December 2025
- Published by Wiley in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
- Vol. 18 (1)
Open AccessPrevalence and predictors of diagnosed mild cognitive impairment among Medicare beneficiaries
INTRODUCTION: Mild cognitive impairment (MCI) is a known risk factor for dementia and presents an opportunity for early engagement in preventative strategies, treatment, and advanced planning. However, little is known about MCI diagnosis rates among Medicare beneficiaries. METHODS: Using data from the 2014 to 2022 rounds of the National Health and Aging Trends Study (NHATS) linked with Medicare claims data, we identified the proportion of beneficiaries with symptoms of MCI, as defined by an NHATS algorithm, who received a diagnosis according to International Classification of Diseases codes. Univariate and multivariate logistic regressions were used to identify predictors of diagnosed MCI. RESULTS: Of beneficiaries identified by the NHATS algorithm, 10.6% had a recorded diagnosis of MCI. Odds of diagnosis were higher among women and beneficiaries with a bachelor's degree or higher, and lower among beneficiaries who attended doctor visits alone. DISCUSSION: Targeted initiatives are needed to increase MCI diagnosis rates, particularly in the era of novel diagnostic tests and therapies. Highlights: We linked National Health and Aging Trends Study data to Medicare claims to identify the prevalence of diagnosed mild cognitive impairment (MCI). We identified 10.6% of Medicare beneficiaries with symptoms of MCI who have a diagnosis. Women and people with a bachelor's degree were more likely to have an MCI diagnosis. People who visited the doctor alone were less likely to have an MCI diagnosis.
- Open Access
- 23 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S6) , e105598
A Latent Profile Analysis of Beliefs about Alzheimer's Disease Risk Factors and Prevention Strategies among Americans Aged 50+
Background: This study aimed to identify distinct patterns of beliefs regarding the importance of Alzheimer's disease (AD) risk factors and the effectiveness of prevention strategies among Americans aged 50+. This information could be used to develop public health interventions to increase engagement in dementia prevention strategies. Method: We analyzed data from 1,819 adults who participated in a single 2010 Health and Retirement Study experimental module on AD knowledge and beliefs. On a 3‐point Likert scale, participants rated the importance of AD risk factors (stress and genetics) for causing AD (1 = not important; 3 = very important) and the effectiveness of prevention strategies (physical activity, mental activity, diet, vitamins) (1 = not effective; 3 = very effective). We performed an unweighted latent profile analysis to identify distinct profiles of beliefs about AD risk factors and prevention strategies and multinomial regression to identify demographic predictors of profile membership. Results: We identified three distinct belief profiles. Profile 1 (63% of participants) were uncertain about the importance of risk factors and the effectiveness of prevention strategies; Profile 2 (15% of participants) strongly believed in the effectiveness of all prevention strategies, and Profile 3 (21% of participants) rated genetics as the most important risk factor but did not believe in the effectiveness of prevention strategies. Having a master's degree or above was associated with Profile 1 membership. Black participants were more likely than White participants to belong to Profiles 2 or 3 (RRR: 2.23 and 2.36, p p = 0.029), and Profile 2 members had higher odds of believing they would develop AD in the future (OR: 1.26, p = 0.05). Conclusions: We found three distinct profiles of beliefs about AD risk factors and prevention strategies. Demographic characteristics, such as education and race, were associated with profile membership but not experience with AD. Public health messaging about AD prevention should be tailored to the beliefs of different demographic groups.
- 23 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S6) , e105598
Open AccessA Latent Profile Analysis of Beliefs about Alzheimer's Disease Risk Factors and Prevention Strategies among Americans Aged 50+
Background: This study aimed to identify distinct patterns of beliefs regarding the importance of Alzheimer's disease (AD) risk factors and the effectiveness of prevention strategies among Americans aged 50+. This information could be used to develop public health interventions to increase engagement in dementia prevention strategies. Method: We analyzed data from 1,819 adults who participated in a single 2010 Health and Retirement Study experimental module on AD knowledge and beliefs. On a 3‐point Likert scale, participants rated the importance of AD risk factors (stress and genetics) for causing AD (1 = not important; 3 = very important) and the effectiveness of prevention strategies (physical activity, mental activity, diet, vitamins) (1 = not effective; 3 = very effective). We performed an unweighted latent profile analysis to identify distinct profiles of beliefs about AD risk factors and prevention strategies and multinomial regression to identify demographic predictors of profile membership. Results: We identified three distinct belief profiles. Profile 1 (63% of participants) were uncertain about the importance of risk factors and the effectiveness of prevention strategies; Profile 2 (15% of participants) strongly believed in the effectiveness of all prevention strategies, and Profile 3 (21% of participants) rated genetics as the most important risk factor but did not believe in the effectiveness of prevention strategies. Having a master's degree or above was associated with Profile 1 membership. Black participants were more likely than White participants to belong to Profiles 2 or 3 (RRR: 2.23 and 2.36, p p = 0.029), and Profile 2 members had higher odds of believing they would develop AD in the future (OR: 1.26, p = 0.05). Conclusions: We found three distinct profiles of beliefs about AD risk factors and prevention strategies. Demographic characteristics, such as education and race, were associated with profile membership but not experience with AD. Public health messaging about AD prevention should be tailored to the beliefs of different demographic groups.
- Open Access
- 23 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S6) , e099946
MCI is underdiagnosed among Medicare beneficiaries in the United States
Background: Mild cognitive impairment (MCI) is a key risk factor for future dementia. Although MCI affects more people than dementia, little is known about MCI diagnosis rates. The aim of this study was to determine the proportion of people with MCI who received a formal diagnosis and identify patient characteristics associated with an MCI diagnosis in a nationally representative sample of Medicare beneficiaries in the United States. Method: This study is a retrospective cohort study data from the National Health and Aging Trends Study (NHATS). NHATS is an annual nationally representative survey of Medicare beneficiaries and includes measures of cognition. We included beneficiaries enrolled in the 2015 round of NHATS, who developed symptoms of cognitive impairment consistent with MCI according to a validated algorithm of NHATS measures of cognition, and were continuously enrolled in Medicare fee‐for‐service. Beneficiaries were followed up until 2022. Beneficiaries with diagnosed MCI were identified in Medicare claims data using ICD‐9 and ICD‐10 codes for MCI. Univariate and multivariate logistic regressions were used to identify patient characteristics associated with diagnosed MCI. Characteristics of interest included age, gender, race and ethnicity, marital status, education, number of children, living alone, visiting the doctor alone, number of co‐morbid conditions, depression, and anxiety. Sample weights were applied to all analyses to generate nationally representative estimates. Result: Of 2.7 million continuously enrolled Medicare beneficiaries with symptoms of cognitive impairment consistent with MCI, only 10.6% had a diagnosis of MCI recorded in claims. Univariate analyses found the odds of diagnosis were lower among younger beneficiaries, higher among women, and lower among beneficiaries who attended doctor visits alone. Multivariate analyses did not find any characteristics significantly associated with diagnosed MCI however, statistical power may have been limited by the small number of beneficiaries with an MCI diagnosis. A sensitivity analysis limiting to significant predictors from the univariate analysis confirmed the association between attending doctor visits alone and undiagnosed MCI. Conclusion: The findings of this study suggest that MCI is significantly underdiagnosed, particularly among Medicare beneficiaries who attend doctor visits alone. Future research and policy initiatives are needed to increase MCI diagnosis rates.
- 23 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S6) , e099946
Open AccessMCI is underdiagnosed among Medicare beneficiaries in the United States
Background: Mild cognitive impairment (MCI) is a key risk factor for future dementia. Although MCI affects more people than dementia, little is known about MCI diagnosis rates. The aim of this study was to determine the proportion of people with MCI who received a formal diagnosis and identify patient characteristics associated with an MCI diagnosis in a nationally representative sample of Medicare beneficiaries in the United States. Method: This study is a retrospective cohort study data from the National Health and Aging Trends Study (NHATS). NHATS is an annual nationally representative survey of Medicare beneficiaries and includes measures of cognition. We included beneficiaries enrolled in the 2015 round of NHATS, who developed symptoms of cognitive impairment consistent with MCI according to a validated algorithm of NHATS measures of cognition, and were continuously enrolled in Medicare fee‐for‐service. Beneficiaries were followed up until 2022. Beneficiaries with diagnosed MCI were identified in Medicare claims data using ICD‐9 and ICD‐10 codes for MCI. Univariate and multivariate logistic regressions were used to identify patient characteristics associated with diagnosed MCI. Characteristics of interest included age, gender, race and ethnicity, marital status, education, number of children, living alone, visiting the doctor alone, number of co‐morbid conditions, depression, and anxiety. Sample weights were applied to all analyses to generate nationally representative estimates. Result: Of 2.7 million continuously enrolled Medicare beneficiaries with symptoms of cognitive impairment consistent with MCI, only 10.6% had a diagnosis of MCI recorded in claims. Univariate analyses found the odds of diagnosis were lower among younger beneficiaries, higher among women, and lower among beneficiaries who attended doctor visits alone. Multivariate analyses did not find any characteristics significantly associated with diagnosed MCI however, statistical power may have been limited by the small number of beneficiaries with an MCI diagnosis. A sensitivity analysis limiting to significant predictors from the univariate analysis confirmed the association between attending doctor visits alone and undiagnosed MCI. Conclusion: The findings of this study suggest that MCI is significantly underdiagnosed, particularly among Medicare beneficiaries who attend doctor visits alone. Future research and policy initiatives are needed to increase MCI diagnosis rates.
- 26 June 2024
- Published by Taylor & Francis in Aging & Mental Health
- Vol. 29 (1) , 112-120
“There has to be more caring”: patient and care partner experiences of the disclosure of amyloid-β PET scan results
ObjectivesTo explore patient and care partner experiences of receiving an amyloid scan result, with a focus on how clinician disclosure practices influenced patient and care partner emotional responses to the scan result and/or diagnosis.MethodsSemi-structured interviews with 38 people with mild cognitive impairment or dementia and 62 care partners who experienced the disclosure of results from an amyloid PET scan as part of the CARE-IDEAS study. We used thematic analysis to analyze interview transcripts.ResultsWe identified four aspects of the disclosure process that could influence patient and care partner emotional experiences of the scan result/diagnosis: (1) mode of delivery, (2) presence of a care partner, (3) clarity of the scan result explanation, and (4) discussion of post-scan treatment and support options.ConclusionsEmotional experiences of an amyloid scan result can vary depending on how results are communicated. These findings support previous efforts to develop standard disclosure protocols. Scan results should be delivered in person with the care partner present. Clinicians should give a clear explanation of the result and its implications in an empathetic manner. Options for treatment and support should be discussed for all patients.
- 26 June 2024
- Published by Taylor & Francis in Aging & Mental Health
- Vol. 29 (1) , 112-120
“There has to be more caring”: patient and care partner experiences of the disclosure of amyloid-β PET scan results
ObjectivesTo explore patient and care partner experiences of receiving an amyloid scan result, with a focus on how clinician disclosure practices influenced patient and care partner emotional responses to the scan result and/or diagnosis.MethodsSemi-structured interviews with 38 people with mild cognitive impairment or dementia and 62 care partners who experienced the disclosure of results from an amyloid PET scan as part of the CARE-IDEAS study. We used thematic analysis to analyze interview transcripts.ResultsWe identified four aspects of the disclosure process that could influence patient and care partner emotional experiences of the scan result/diagnosis: (1) mode of delivery, (2) presence of a care partner, (3) clarity of the scan result explanation, and (4) discussion of post-scan treatment and support options.ConclusionsEmotional experiences of an amyloid scan result can vary depending on how results are communicated. These findings support previous efforts to develop standard disclosure protocols. Scan results should be delivered in person with the care partner present. Clinicians should give a clear explanation of the result and its implications in an empathetic manner. Options for treatment and support should be discussed for all patients.
- 13 June 2024
- Published by Oxford University Press (OUP) in The Gerontologist
- Vol. 64 (8)
Persons With Cognitive Impairment and Care Partner Motivations and Experiences of Undergoing an Amyloid Scan: A Systematic Review of Qualitative Studies
Background and Objectives: Amyloid positron emission tomography scans can enhance the accuracy of dementia diagnoses. However, the perspectives and experiences of people with cognitive impairment and their care partners undergoing an amyloid scan are less well understood. Therefore, this review aimed to identify and summarize qualitative studies exploring patient and care partner experiences of undergoing an amyloid scan. Research Design and Methods: We searched Embase, MEDLINE, and PsychInfo in March 2024. Articles were screened for inclusion by 2 reviewers and critically appraised using the Joanna Briggs Institute Critical Appraisal Tool for Qualitative Studies. Data from the included studies were synthesized using thematic synthesis. Results: We identified 10 papers from 6 studies. We identified 4 themes: (1) motivations for undergoing an amyloid scan, (2) experiences of receiving the result, (3) emotional responses to the result, and (4) actions in light of the scan result. Participants reported undergoing the scan to determine the cause of cognitive impairment. They described the information gained from the scan as helpful but struggled to recall the correct terminology or implications of the scan. Emotional responses to the scan varied depending on the scan result. In light of the scan result, the most common action was making advanced plans; however, this was mainly discussed among participants with elevated amyloid. Discussions and Implications: Amyloid scans can provide useful and actionable information. However, learning the scan result could be distressing. Future research is needed to balance the potential benefits and harms of amyloid scans.
- 13 June 2024
- Published by Oxford University Press (OUP) in The Gerontologist
- Vol. 64 (8)
Persons With Cognitive Impairment and Care Partner Motivations and Experiences of Undergoing an Amyloid Scan: A Systematic Review of Qualitative Studies
Background and Objectives: Amyloid positron emission tomography scans can enhance the accuracy of dementia diagnoses. However, the perspectives and experiences of people with cognitive impairment and their care partners undergoing an amyloid scan are less well understood. Therefore, this review aimed to identify and summarize qualitative studies exploring patient and care partner experiences of undergoing an amyloid scan. Research Design and Methods: We searched Embase, MEDLINE, and PsychInfo in March 2024. Articles were screened for inclusion by 2 reviewers and critically appraised using the Joanna Briggs Institute Critical Appraisal Tool for Qualitative Studies. Data from the included studies were synthesized using thematic synthesis. Results: We identified 10 papers from 6 studies. We identified 4 themes: (1) motivations for undergoing an amyloid scan, (2) experiences of receiving the result, (3) emotional responses to the result, and (4) actions in light of the scan result. Participants reported undergoing the scan to determine the cause of cognitive impairment. They described the information gained from the scan as helpful but struggled to recall the correct terminology or implications of the scan. Emotional responses to the scan varied depending on the scan result. In light of the scan result, the most common action was making advanced plans; however, this was mainly discussed among participants with elevated amyloid. Discussions and Implications: Amyloid scans can provide useful and actionable information. However, learning the scan result could be distressing. Future research is needed to balance the potential benefits and harms of amyloid scans.
- Open Access
- 24 April 2024
- Published by Springer Nature in BMC Health Services Research
- Vol. 24 (1) , 1-11
A qualitative study of informal caregiver perceptions of the benefits of an early dementia diagnosis
Background: Current and former dementia policies in the United Kingdom (UK) recommend diagnosing dementia early, or as close to the onset of symptoms as possible. Informal caregivers play an important role in initiating the diagnostic process and providing support to people living with dementia. Therefore, this study aimed to explore caregiver perceptions of the benefits of an early diagnosis. Methods: We conducted semi-structured interviews with 12 current and former informal caregivers to people with dementia in the UK in 2020. We analysed the interviews using thematic analysis. Results: Benefits of an early diagnosis included: (1) protecting the person with dementia from financial or physical harm, (2) timely decision-making, and (3) access to services and treatments following a diagnosis. We identified three conditions necessary for the benefits of an early diagnosis to be felt: (1) adequate prognostic information, (2) someone to advocate on behalf of the person with dementia, and (3) a willingness to seek and accept the diagnosis. Conclusions: In this study, we identified how diagnosing dementia close to the onset of symptoms could be beneficial and the conditions necessary for these benefits to be felt. The findings highlight the importance of an early diagnosis for enabling people with dementia and caregivers to make practical arrangements and to access services. Further research is needed to build on the findings of this study by exploring the perspectives of people with dementia and by including a larger, more diverse sample of caregivers.
- 24 April 2024
- Published by Springer Nature in BMC Health Services Research
- Vol. 24 (1) , 1-11
Open AccessA qualitative study of informal caregiver perceptions of the benefits of an early dementia diagnosis
Background: Current and former dementia policies in the United Kingdom (UK) recommend diagnosing dementia early, or as close to the onset of symptoms as possible. Informal caregivers play an important role in initiating the diagnostic process and providing support to people living with dementia. Therefore, this study aimed to explore caregiver perceptions of the benefits of an early diagnosis. Methods: We conducted semi-structured interviews with 12 current and former informal caregivers to people with dementia in the UK in 2020. We analysed the interviews using thematic analysis. Results: Benefits of an early diagnosis included: (1) protecting the person with dementia from financial or physical harm, (2) timely decision-making, and (3) access to services and treatments following a diagnosis. We identified three conditions necessary for the benefits of an early diagnosis to be felt: (1) adequate prognostic information, (2) someone to advocate on behalf of the person with dementia, and (3) a willingness to seek and accept the diagnosis. Conclusions: In this study, we identified how diagnosing dementia close to the onset of symptoms could be beneficial and the conditions necessary for these benefits to be felt. The findings highlight the importance of an early diagnosis for enabling people with dementia and caregivers to make practical arrangements and to access services. Further research is needed to build on the findings of this study by exploring the perspectives of people with dementia and by including a larger, more diverse sample of caregivers.
- 24 July 2023
- Published by Wolters Kluwer Health in Alzheimer Disease & Associated Disorders
- Vol. 37 (3) , 246-258
Psychosocial and Behavioral Outcomes for Persons With Cognitive Impairment and Caregivers Following Amyloid-β PET Scan Disclosure
Background: Positron emission tomography (PET) scans for amyloid-β can aid in the early and accurate detection of Alzheimer disease. The results of amyloid PET scans could help people with cognitive impairment and caregivers better understand their diagnosis; however, there are concerns that they could also cause psychological harm. Methods: A systematic review of psychosocial and behavioral quantitative outcomes following the disclosure of an amyloid PET scan for persons living with cognitive impairment (subjective cognitive decline, mild cognitive impairment, Alzheimer’s Disease, and other dementias) and caregivers. Findings: Ten papers were identified from 7 studies. There was little evidence of an association between disclosure and depression. However, persons with mild cognitive impairment and their caregivers with elevated levels of amyloid had an increased risk of distress or anxiety compared with those without elevated amyloid. Participants correctly recalled the scan results; however, it is unclear whether this led to an increased understanding of their diagnosis. We did not identify any studies measuring behavioral outcomes. Conclusions: We found mixed evidence on the relationship between amyloid scans and psychosocial and behavioral outcomes in people with cognitive impairment and caregivers. These findings highlight the need for more methodologically rigorous research on this topic.
- 24 July 2023
- Published by Wolters Kluwer Health in Alzheimer Disease & Associated Disorders
- Vol. 37 (3) , 246-258
Psychosocial and Behavioral Outcomes for Persons With Cognitive Impairment and Caregivers Following Amyloid-β PET Scan Disclosure
Background: Positron emission tomography (PET) scans for amyloid-β can aid in the early and accurate detection of Alzheimer disease. The results of amyloid PET scans could help people with cognitive impairment and caregivers better understand their diagnosis; however, there are concerns that they could also cause psychological harm. Methods: A systematic review of psychosocial and behavioral quantitative outcomes following the disclosure of an amyloid PET scan for persons living with cognitive impairment (subjective cognitive decline, mild cognitive impairment, Alzheimer’s Disease, and other dementias) and caregivers. Findings: Ten papers were identified from 7 studies. There was little evidence of an association between disclosure and depression. However, persons with mild cognitive impairment and their caregivers with elevated levels of amyloid had an increased risk of distress or anxiety compared with those without elevated amyloid. Participants correctly recalled the scan results; however, it is unclear whether this led to an increased understanding of their diagnosis. We did not identify any studies measuring behavioral outcomes. Conclusions: We found mixed evidence on the relationship between amyloid scans and psychosocial and behavioral outcomes in people with cognitive impairment and caregivers. These findings highlight the need for more methodologically rigorous research on this topic.